Pfizer and Moderna are preventing scientists from using their current vaccines for research. The U.S. should act now to restore competition.
intellectual property
Posted inHealth and Social Policy
The Obscure NIH Official Blocking Lower Drug Prices
Mark Rohrbaugh, a mid-level staffer at the National Institutes of Health, has consistently blocked the use of march-in rights to seize patents on high-cost drugs.
Posted inEconomic Policy
A Return to Rentiership
A new paper shows that rent-seeking by firms with dominant market positions has exploded since the 1980s.
Posted inHealth and Social Policy
Merck Says Negotiating Drug Prices Is Unconstitutional
The Inflation Reduction Act took minor steps against Big Pharma price-gouging. Merck is outraged.
Posted inHealth and Social Policy
How Big Pharma Rigged the Patent System
Drug patents are supposed to expire in 20 years. Thanks to legal trickery, though, it usually takes a lot longer than that.
Posted inEducation in America
The Companies AI Might Replace Aren’t Exactly Good
A review of Chegg, an online education tutor that’s threatened by ChatGPT, suggests that a bigger problem than AI is what we allow businesses to get away with.
Posted inMoney, Politics, and Power
Big Tech Lobbyists Explain How They Took Over Washington
An amazing research paper unearths how the tech industry invented the concept of digital trade and sold it to government officials.
Posted inHealth and Social Policy
India Decides Fighting Tuberculosis Is More Important Than Johnson & Johnson’s Profits
The country shot down a patent extension on a critical TB drug.
Posted inTAP
A Big Miss on Drug Prices
Today on Tap: President Biden’s NIH rejects a petition to seize the patent of an unaffordable prescription drug.
Posted inTAP
Bipartisanship in the House
Today on TAP: As the China menace keeps ballooning, the House Select Committee on China appears to be a serious undertaking.